Science
Hidehito Horinouchi: CNS Radiotherapy in EGFR-Mutant NSCLC with Synchronous Brain Metastasis
Hidehito Horinouchi/X

Hidehito Horinouchi: CNS Radiotherapy in EGFR-Mutant NSCLC with Synchronous Brain Metastasis

Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared on X:

“CNS radiotherapy in EGFR-mutant NSCLC with synchronous brain metastasis.

  • N=244; upfront SRS-TKI vs WBRT-TKI vs TKI-only: osimertinib without upfront SRS may be reasonable
  • Upfront WBRT reduced CNS progression (HR 0.29), esp. L858R (HR 0.17); L858R linked to inferior OS.”

Title: Impact of CNS radiotherapy on outcomes in metastatic EGFR-mutant non-small cell lung cancer with synchronous brain metastasis

Authors: Erjia Zhu, Lingzhi Hong, Ji Z. Lin, Sahana Ramasamy, J. Pierce Reitnauer, Ran An, Kelsey Pan, Kaiwen Wang, Ara A. Vaporciyan, Don L. Gibbons, J. Jack Lee, Hai Tran, Hong Chen, Ximeng Liu, Jianjun Zhang, Monique Nilsson, Jia Wu, Jing Li, John V. Heymach, Thomas H. Beckham, Xiuning Le.

Read the full article.

You can also read:

FLASH SRS With Proton Bragg Peak Tracking Achieves IMPT Equivalent Brain Metastasis Dosimetry

Hidehito Horinouchi: CNS Radiotherapy in EGFR-Mutant NSCLC with Synchronous Brain Metastasis

Ara A. Vaporciyan brain metastasis cancer CNS CNS Radiotherapy Don L. Gibbons EGFR-mutant NSCLC Erjia Zhu Hai Tran Hidehito Horinouchi Hong Chen J Jack Lee J. Pierce Reitnauer Ji Z. Lin Jia Wu Jianjun Zhang Jing Li John V. Heymach Kaiwen Wang Kelsey Pan Lingzhi Hong Lung cancer Monique Nilsson non small cell lung cancer NSCLC OncoDaily Oncology osimertinib Ran An Sahana Ramasamy Thomas H. Beckham WBRT Ximeng Liu Xiuning Le